Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | SCN4A | P35499 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25002316 | 0.85 | TSHR (0.33) | TSHRLMNACYP3A4NFKB1ADRA1A | |
| SCHEMBL23453068 | 0.85 | TSHR (0.33) | TSHRLMNACYP3A4NFKB1ADRA1A | |
| SCHEMBL19733797 | 0.85 | POLB (0.33) | TSHRLMNACYP3A4NFKB1ADRA1A | |
| SCHEMBL24993699 | 0.83 | SCN4A (0.32) | TSHRLMNACYP3A4NFKB1ADRA1A | |
| SCHEMBL11977974 | 0.82 | CTSK (0.47) | EPHX1CTSKLMNA | |
| SCHEMBL18748770 | 0.82 | EPHX1 (0.37) | EPHX1LMNANFKB1RAB9A | |
| SCHEMBL25572170 | 0.81 | TSHR (0.30) | TSHRLMNACYP3A4NFKB1ADRA1A | |
| SCHEMBL21970968 | 0.80 | CYP19A1 (0.34) | EPHX1TSHRCTSKLMNA | |
| SCHEMBL21309954 | 0.80 | CYP19A1 (0.34) | EPHX1TSHRCTSKLMNA | |
| SCHEMBL13293247 | 0.80 | CTSK (0.45) | TSHRCTSKLMNACYP3A4NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330562-A1 | METHODS OF PREPARING PROTEIN-OLIGONUCLEOTIDE COMPLEXES | DYNE THERAPEUTICS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330562-A1 | METHODS OF PREPARING PROTEIN-OLIGONUCLEOTIDE COMPLEXES | PHAX, RAB5IF, CD2BP2 | EPHX1 4214/4885TSHR 2074/4885CTSK 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.